Effective January 1, 2017 - New permanent J-code for ONIVYDE®: J9205, injection, irinotecan liposome, 1 mg This information is presented for informational purposes only and is not intended to provide reimbursement or legal advice.

FOR US HEALTHCARE PROFESSIONALS ONLY Call Us at (844) 441-6225

Designed For Prolonged Exposure1,2

ONIVYDE® (irinotecan liposome injection) is an encapsulation of irinotecan in a long-circulating liposome

  • The half-life (T1/2) of total irinotecan following administration of ONIVYDE® 70 mg/m2 is 25.8 hours
  • 95% of irinotecan remains contained within the liposome during circulation
    • The ratio between total and encapsulated forms did not change from 0 to 169.5 hours post-dose
  • In mice bearing human tumor xenografts, ONIVYDE® achieved similar intratumoral exposure of SN-38 at a 5-fold lower dose than irinotecan HCl
ONIVYDE® (irinotecan liposome injection)

HCl=hydrochloride; PEG-DSPE=polyethylene glycol-distearoylphosphatidylethanolamine.

INDICATION AND IMPORTANT SAFETY INFORMATION

**National Comprehensive Cancer Network® (NCCN®).

References: 1. ONIVYDE® Full Prescribing Information. 2. Data on file. Basking Ridge, NJ; Ipsen Biopharmaceuticals, Inc.

EXPAND

INDICATION AND IMPORTANT
SAFETY INFORMATION